A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011 — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011 — Stella

Recruiting

Back to Acute Gout Flare trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu

Key details

Phase

Early testing

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Enrollment target

~64 participants

Started

December 2025

Primary completion

June 2026

Age range

18 Years – 100 Years

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov